NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Oral GnRH-Ant Elagolix to Patients With Surgically Diagnosed Endometriosis – RBMO
RBMO/LinkedIn
Feb 24, 2026, 09:00

Oral GnRH-Ant Elagolix to Patients With Surgically Diagnosed Endometriosis – RBMO

Reproductive BioMedicine Online shared a post on LinkedIn about a paper by Eric S. Surrey et al. published in RBMO:

“This prospective, randomized, pilot trial demonstrates that administration of the oral GnRH-ant elagolix to patients with surgically diagnosed endometriosis for 56 days before euploid embryo transfer resulted in highly encouraging outcomes that were not only non-inferior but apparently equivalent to a similar group of patients reviewing a parenteral GnRHa for a similar time period.

Authors Eric Surrey, Mandy Katz-Jaffe, Laxmi A Kondapalli, William Schoolcraft, and Rachel Makloski say that, if these results are confirmed in larger scale appropriately designed trials, this agent could be a more tolerable substitute for long acting GnRHa as has been suggested in trials of symptomatic endometriosis patients – the development of non-invasive serum or endometrial markers to determine which patients would be most likely to benefit from this treatment would be invaluable.

Selected as an Editor’s Choice article from our December issue, the paper can be read in full for free, now.”

Title: Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial

Oral GnRH-Ant Elagolix to Patients With Surgically Diagnosed Endometriosis – RBMO

Stay updated on all scientific advances in the field of fertility with Fertility News.

NewsFeed